VisionHealth GmbH
About us
About VisionHealth:
VisionHealth is specialized in Digital Therapeutics for Inhaled Medicines. Our aspiration is to redefine adherence and maximize the benefit of inhaled therapies
We develop disease-specific, flexible health solutions targeting:
Quality of inhaled drug delivery
Better patient self-management
Improved clinical and health-economic disease outcomes
Our AI-based Kata® smartphone application is supported by clinical evidence, and FDA approved/CE marked as a medical device.
Address
Landsberger Straße 72
80339 München
Germany
E-mail: info@visionhealth.gmbh
Phone: +49 89 614242900
Internet: visionhealth.gmbh
6 Dairy Farm Lane
MA 01778 Wayland
United States
E-mail: info@visionhealth.gmbh
Phone: +49 89 614242900
Internet: visionhealth.gmbh/en/
Contact person:
Products & Services
About Kata®:
Kata is an AI-driven digital therapeutic inhalation coach for chronically inhaled drug-device products (used in Asthma, COPD, IPF, Cystic Fibrosis, Pulmonary Hypertension). Kata only requires a patient’s smartphone and is customizable to any inhaler device. Easy to scale, Kata is FDA licensed as a type 1 medical Device & CE marked in the EU (Type II device).
Inhalation is not easy for patients, with frequent handling errors (up to 80%) and minimal or no drug dose reaching the lung. Training in real-time, at the patient’s home, is complex and costly for health systems. Lack of “real” adherence control is a major issue for patients, caregivers, physicians, pharma manufacturers and payers, in clinical research and in-market stages .
Kata’s unique patient-centric technology reduces critical patient handling errors by 100%. It analyzes each inhalation and provides real-time coaching to the patient to improve their technique. The result is consistent delivery of indicated drug dose to the lung. Kata helps patients fully benefit from their treatment and reduces complications, saving health care resources. In our Phase 2 GIANT Study, presented at ERS 2024, the reduction in inhalations errors and better treatment adherence in patients, led to a significant improvement in Asthma Control, as measured by the ACQ score.
In short, Kata enables the full potential of inhaled drugs and redefines adherence "quality" and disease management with real-time intervention and data analytics.